Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Redefining the "aging brain" through diverse data

9

Mar 2026

Redefining the "aging brain" through diverse data

Age is more than just one number. While neuroscientists used to think of cognitive aging as a single trendline, they now realize that vast individual differences require a more predictive and personalized approach. As they uncover more factors that affect cognition over time, they are realizing that modeling the aging brain requires more diverse data than traditionally captured.

Targeting Wnt signaling to solve the dental pulp challenge

9

Mar 2026

Targeting Wnt signaling to solve the dental pulp challenge

Dental pulp regeneration remains a major clinical challenge. Researchers have discovered that SMAD7 directly forms a transcriptional complex with β-catenin in human dental pulp stem cells, activating Wnt signaling and promoting regenerative gene expression.

Navigating the structural challenges of AI in radiology

9

Mar 2026

Navigating the structural challenges of AI in radiology

Artificial intelligence (AI) has the potential to redefine how radiology is practiced, as well as highlight specific challenges for radiology departments, according to new research from the Journal of the American College of Radiology (JACR).

New peptide fragments teach the gut to tolerate food

9

Mar 2026

New peptide fragments teach the gut to tolerate food

In little moments like when sipping coffee or licking an ice cream cone, it doesn't seem like your body is pulling off a biological miracle. But it is. That cookie is not you-yet when you put it in your mouth, your body is able to tolerate it and process it without any detriment to your health in a process called oral tolerance. How does the human body make that decision between tolerance and rejection?

Could GLP-1 drugs help curb addiction? Large veteran study points to potential benefit

8

Mar 2026

Could GLP-1 drugs help curb addiction? Large veteran study points to potential benefit

A large cohort study of more than 600,000 US veterans with type 2 diabetes found that initiating GLP-1 receptor agonists was associated with lower risks of developing substance use disorders compared with SGLT-2 inhibitors. Among veterans with existing substance use disorders, GLP-1 receptor agonist use was also linked to fewer overdose events, hospitalizations, and suicide-related outcomes.

How somatic mutations shape disease and reveal new drug targets

8

Mar 2026

How somatic mutations shape disease and reveal new drug targets

Researchers reviewed how somatic mutations accumulate in normal and diseased tissues, showing that natural selection can expand clones that influence disease risk, tissue adaptation, or cellular resilience. The study proposes somatic genomics as a powerful strategy to uncover disease mechanisms and identify new therapeutic targets across multiple conditions.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.